Mohammed Osman1, Mohammad Elkady2. 1. General Organization for Teaching Hospital, Cairo, Egypt. 2. Ain Shams University, Cairo, Egypt.
Abstract
BACKGROUND: The primary objective of the study was to evaluate the long-term changes in ejection fraction (EF) associated with paclitaxel infusion. METHODS: 50 patients were enrolled in this prospective study between 2011 and 2015. The study design included frequent follow-up visits to the clinic, EF evaluation at baseline, and regular EF assessment by echocardiography for 30 months after treatment. RESULTS: The median baseline EF was 60% (95% confidence interval (CI) 50-80%). At 30 months, the median EF was 48% (95% CI 40-60%; p = 0.03). During the 30-month follow-up, 10 (20%) patients developed grade 1 and 2 cardiotoxicities; none developed grade 3 or 4 cardiotoxicities. Furthermore, paclitaxel cardiotoxicity increased among patients with high-risk features including associated diabetes mellitus, hypertension, prior radiotherapy to the chest wall, performance status of 2, and age > 60 years. CONCLUSION: Paclitaxel has cardiotoxic effects. Careful monitoring of cardiac function during and after paclitaxel infusion is required in patients with high-risk features.
BACKGROUND: The primary objective of the study was to evaluate the long-term changes in ejection fraction (EF) associated with paclitaxel infusion. METHODS: 50 patients were enrolled in this prospective study between 2011 and 2015. The study design included frequent follow-up visits to the clinic, EF evaluation at baseline, and regular EF assessment by echocardiography for 30 months after treatment. RESULTS: The median baseline EF was 60% (95% confidence interval (CI) 50-80%). At 30 months, the median EF was 48% (95% CI 40-60%; p = 0.03). During the 30-month follow-up, 10 (20%) patients developed grade 1 and 2 cardiotoxicities; none developed grade 3 or 4 cardiotoxicities. Furthermore, paclitaxelcardiotoxicity increased among patients with high-risk features including associated diabetes mellitus, hypertension, prior radiotherapy to the chest wall, performance status of 2, and age > 60 years. CONCLUSION:Paclitaxel has cardiotoxic effects. Careful monitoring of cardiac function during and after paclitaxel infusion is required in patients with high-risk features.
Authors: Aarif Y Khakoo; Peter P Liu; Thomas Force; Gabriel Lopez-Berestein; Lee W Jones; Jay Schneider; Joseph Hill Journal: Tex Heart Inst J Date: 2011
Authors: L Del Mastro; F Perrone; L Repetto; L Manzione; V Zagonel; L Fratino; D Marenco; M Venturini; E Maggi; C Bighin; T Catzeddu; A Venturino; R Rosso Journal: Ann Oncol Date: 2005-02 Impact factor: 32.976
Authors: Edward H Romond; Jong-Hyeon Jeong; Priya Rastogi; Sandra M Swain; Charles E Geyer; Michael S Ewer; Vikas Rathi; Louis Fehrenbacher; Adam Brufsky; Catherine A Azar; Patrick J Flynn; John L Zapas; Jonathan Polikoff; Howard M Gross; David D Biggs; James N Atkins; Elizabeth Tan-Chiu; Ping Zheng; Greg Yothers; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2012-09-17 Impact factor: 44.544
Authors: L Gianni; E Munzone; G Capri; F Villani; C Spreafico; E Tarenzi; F Fulfaro; A Caraceni; C Martini; A Laffranchi Journal: J Natl Cancer Inst Date: 1995-08-02 Impact factor: 13.506
Authors: Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter Journal: Eur Heart J Date: 2016-08-26 Impact factor: 29.983
Authors: E Baldini; T Prochilo; B Salvadori; A Bolognesi; D Aldrighetti; M Venturini; R Rosso; F Carnino; L Gallo; P Giannessi; P F Conte; C Orlandini; P Bruzzi Journal: Br J Cancer Date: 2004-07-05 Impact factor: 7.640
Authors: Marco Bruno Morelli; Chiara Bongiovanni; Silvia Da Pra; Carmen Miano; Francesca Sacchi; Mattia Lauriola; Gabriele D'Uva Journal: Front Cardiovasc Med Date: 2022-04-15